You’re invited to provide comments on proposed amendments to the Patented Medicines Regulations.
The amendments would enable the Patented Medicine Prices Review Board to better protect Canadians from paying excessive prices for patented drugs.
The regulations have not been changed in over 20 years, despite major changes in the pharmaceutical market. Canadians are now paying some of the highest drug prices in the developed world. This impacts patients and the sustainability of Canada’s health care system.
We are committed to improving the affordability, accessibility and appropriate use of prescription drugs to better meet health care system needs. This important work includes reducing the cost of prescription drugs by updating the patented drug pricing framework.
We are seeking feedback on proposed amendments to the regulations, prior to their pre-publication in Part I of the Canada Gazette, from:
- consumer groups
- federal drug plans
- health professionals
- health researchers
- pharmaceutical industry
- private insurers
- provincial and territorial drug plans
- other stakeholders
- any interested members of the public
Health Canada is looking for comments on the following regulatory proposal:
Consultation: proposed amendments to the Patented Medicines Regulations
Amendments are being proposed in order to provide the Patented Medicine Prices Review Board with new regulatory tools and information to better protect Canadian consumers.
The proposed amendments include:
- revising the list of comparator countries used to determine whether a price is excessive
- introducing other factors so that value for money and affordability can be taken into consideration
- updating the information required from patentees
**Please note the consultation period has ended. To view a joint submission prepared by the Canadian Cancer Survivor Network along with 16 other organizations, please click here.